Peter Öhlschläger

1.1k total citations
20 papers, 924 citations indexed

About

Peter Öhlschläger is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Peter Öhlschläger has authored 20 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 8 papers in Molecular Biology and 7 papers in Epidemiology. Recurrent topics in Peter Öhlschläger's work include Immunotherapy and Immune Responses (11 papers), Cervical Cancer and HPV Research (6 papers) and Ferrocene Chemistry and Applications (4 papers). Peter Öhlschläger is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Cervical Cancer and HPV Research (6 papers) and Ferrocene Chemistry and Applications (4 papers). Peter Öhlschläger collaborates with scholars based in Germany, Saudi Arabia and Hungary. Peter Öhlschläger's co-authors include Lutz Gissmann, Wolfram Osen, Alexander Schütz, Richard Moriggl, Kurt Zatloukal, Lukas A. Huber, Hartmut Beug, Karl-Jürgen Halbhuber, Stephan N. Wagner and Daniela Baus and has published in prestigious journals such as PLoS ONE, Chemical Communications and Journal of Virology.

In The Last Decade

Peter Öhlschläger

20 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Öhlschläger Germany 16 374 363 339 247 99 20 924
Shiyin Yao United States 20 230 0.6× 618 1.7× 559 1.6× 165 0.7× 98 1.0× 49 1.3k
Kenia G. Krauer Australia 17 426 1.1× 294 0.8× 509 1.5× 138 0.6× 85 0.9× 34 1.2k
Mathias Rickert United States 10 319 0.9× 710 2.0× 306 0.9× 122 0.5× 96 1.0× 15 1.2k
Raymond P. Baumann United States 21 267 0.7× 184 0.5× 399 1.2× 517 2.1× 77 0.8× 50 1.1k
Huili Lu China 20 316 0.8× 242 0.7× 481 1.4× 78 0.3× 103 1.0× 65 1.0k
Martin Deeg Germany 15 183 0.5× 277 0.8× 663 2.0× 68 0.3× 92 0.9× 31 1.1k
Zhenjian Du United States 12 209 0.6× 317 0.9× 457 1.3× 247 1.0× 47 0.5× 22 1.2k
M. Brett Waddell United States 15 480 1.3× 252 0.7× 1.3k 3.8× 277 1.1× 98 1.0× 23 1.7k
Subhendu Das United States 18 276 0.7× 208 0.6× 733 2.2× 448 1.8× 49 0.5× 26 1.4k
Latha Pathangey United States 16 323 0.9× 444 1.2× 483 1.4× 40 0.2× 151 1.5× 26 1.1k

Countries citing papers authored by Peter Öhlschläger

Since Specialization
Citations

This map shows the geographic impact of Peter Öhlschläger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Öhlschläger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Öhlschläger more than expected).

Fields of papers citing papers by Peter Öhlschläger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Öhlschläger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Öhlschläger. The network helps show where Peter Öhlschläger may publish in the future.

Co-authorship network of co-authors of Peter Öhlschläger

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Öhlschläger. A scholar is included among the top collaborators of Peter Öhlschläger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Öhlschläger. Peter Öhlschläger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Farrag, Mohamed A., et al.. (2017). Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency. Human Vaccines & Immunotherapeutics. 13(7). 1586–1597. 1 indexed citations
2.
Almajhdi, Fahad N., Tilo Senger, Haitham M. Amer, Lutz Gissmann, & Peter Öhlschläger. (2014). Design of a Highly Effective Therapeutic HPV16 E6/E7-Specific DNA Vaccine: Optimization by Different Ways of Sequence Rearrangements (Shuffling). PLoS ONE. 9(11). e113461–e113461. 15 indexed citations
3.
Werner, Carl Frederik, M. Biselli, Peter Öhlschläger, et al.. (2014). Toward multi‐analyte bioarray sensors: LAPS‐based on‐chip determination of a Michaelis–Menten‐like kinetics for cell culturing. physica status solidi (a). 211(6). 1410–1415. 5 indexed citations
4.
Öhlschläger, Peter, et al.. (2014). Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. BMC Cancer. 14(1). 35 indexed citations
5.
Grützke, Martin, et al.. (2012). Synthesis and X-ray structure analysis of a heptacoordinate titanium(iv)-bis-chelate with enhanced in vivo antitumor efficacy. Chemical Communications. 48(46). 5790–5790. 57 indexed citations
6.
Leurs, Ulrike, Eszter Lajkó, Gábor Mező, et al.. (2012). GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. European Journal of Medicinal Chemistry. 52. 173–183. 22 indexed citations
7.
Henken, Florianne E, Koen Oosterhuis, Peter Öhlschläger, et al.. (2012). Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine. 30(28). 4259–4266. 10 indexed citations
8.
Reichardt, Wilfried, et al.. (2011). An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma. Molecular Therapy. 20(3). 555–564. 12 indexed citations
9.
Groth, Ulrich, et al.. (2011). Titanium Salan Complexes Displays Strong Antitumor Properties In Vitro and In Vivo in Mice. PLoS ONE. 6(3). e17869–e17869. 47 indexed citations
10.
Oosterhuis, Koen, Peter Öhlschläger, Joost H. van den Berg, et al.. (2011). Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. International Journal of Cancer. 129(2). 397–406. 29 indexed citations
11.
Leurs, Ulrike, Gábor Mező, Erika Orbán, et al.. (2011). Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug‐bioconjugates containing GnRH‐III as a targeting moiety. Biopolymers. 98(1). 1–10. 18 indexed citations
12.
Manea, Marilena, Ulrike Leurs, Erika Orbán, et al.. (2011). Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4. Bioconjugate Chemistry. 22(7). 1320–1329. 28 indexed citations
13.
Öhlschläger, Peter, et al.. (2010). The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA. International Journal of Cancer. 128(2). 473–481. 32 indexed citations
14.
Öhlschläger, Peter, Michael Quetting, Gerardo Álvarez-Hernández, et al.. (2009). Enhancement of immunogenicity of a therapeutic cervical cancer DNA‐based vaccine by co‐application of sequence‐optimized genetic adjuvants. International Journal of Cancer. 125(1). 189–198. 30 indexed citations
15.
Öhlschläger, Peter, Wolfram Osen, Matthias Dürst, et al.. (2006). An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine. 24(15). 2880–2893. 52 indexed citations
16.
Corvinus, Florian, Richard Moriggl, Stephan N. Wagner, et al.. (2005). Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth. Neoplasia. 7(6). 545–555. 337 indexed citations
17.
Steinberg, Thorsten, Peter Öhlschläger, Peter Sehr, Wolfram Osen, & Lutz Gissmann. (2004). Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine. 23(9). 1149–1157. 30 indexed citations
18.
Öhlschläger, Peter, Wolfram Osen, Stefan Faath, et al.. (2003). Human Papillomavirus Type 16 L1 Capsomeres Induce L1-Specific Cytotoxic T Lymphocytes and Tumor Regression in C57BL/6 Mice. Journal of Virology. 77(8). 4635–4645. 87 indexed citations
19.
Michel, Nico, Peter Öhlschläger, Wolfram Osen, et al.. (2002). T Cell Response to Human Papillomavirus 16 E7 in Mice: Comparison of Cr Release Assay, Intracellular IFN-γ Production, ELISPOT and Tetramer Staining. Intervirology. 45(4-6). 290–299. 25 indexed citations
20.
Osen, Wolfram, Peter Öhlschläger, Sandra Caldeira, et al.. (2001). A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine. 19(30). 4276–4286. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiyin Yao Breakdown of academic impact, for papers by Kenia G. Krauer Breakdown of academic impact, for papers by Mathias Rickert Breakdown of academic impact, for papers by Raymond P. Baumann Breakdown of academic impact, for papers by Huili Lu Breakdown of academic impact, for papers by Martin Deeg Breakdown of academic impact, for papers by Zhenjian Du Breakdown of academic impact, for papers by M. Brett Waddell Breakdown of academic impact, for papers by Subhendu Das Breakdown of academic impact, for papers by Latha Pathangey
Rankless by CCL
2026